Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with RR-MS, according to the revised McDonald Criteria (2010)~* Participants with an expanded disability status scale (EDSS) score between 0 and 3 before screening visit and before relapse~* Participants receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6 months but for no more than 10 years before the screening visit~* Female participants must be neither pregnant nor breastfeeding and must lack childbearing potential~* Participants willing and able to comply with the protocol for the total duration of the study~* Participants able to understand the purposes and the risks of the study~* Participants have signed the appropriate written informed consent form, approved by the Independent Ethics Committee (IEC), prior to the performance of any study activities~* For MS participants with relapse:~* Deterioration of at least one step in a relevant Functional Systems Scale (FSS) or an increase in EDSS of 1 point or more compatible, according to physician's judgment, with the therapy prosecution~* Relapse started within maximum 5 days before the inclusion in the study~* MS participants without relapse with clinically stable RR-MS~Exclusion Criteria:~* Participants with diagnosis of primary progressive MS (PP-MS)~* Participants have any disease other than MS that could better explain his/her signs and symptoms~* Participants with any comorbidity with diseases that might alter synaptic plasticity (example Parkinson Disease, Alzheimer Disease, Stroke)~* Participants receiving concomitant treatment with drugs that may alter synaptic plasticity (example, cannabinoids)~* Participants with history or presence of any unstable medical condition (tumor or chronic infection or severe life threatening infection within the last 6 months)~* Participants who have received any corticosteroids therapy within 3 months prior to the screening~* Participants with any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressive agents during the course of the study~* Participants who have received any immunosuppressive agents other to corticosteroids, as monotherapy or combination therapy within 3 months prior to the screening visit~* Participants with history or currently active primary or secondary immunodeficiency~* Participants with inadequate liver function, defined by alanine aminotransferase (ALT) \> 3 \* upper limit of normal (ULN), or alkaline phosphatase (AP) \> 2 \* ULN, or total bilirubin \> 2 \* ULN if associated with any elevation of ALT or AP~* Participants with inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 \* lower limit of normal (LLN)~* Participants with moderate to severe renal impairment~* Participants unable to complete an magnetic resonance imaging (MRI) (contraindications for MRI include but are not restricted to weight \>=140 kilogram (kg), pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc)~* Participants with contraindication to gadolinium (Gd) can be enrolled into the study but cannot receive Gd contrast dyes during their MRI scans~* Participants receiving supplements that, in the Investigator's opinion, may affect the evaluation of fatigue~* Participants with any known contraindications or hypersensitivity to D-aspartate or any excipient~* Participants with any other significant disease that in the Investigator's opinion would impede study assessments or endanger the participant~* Female participants with positive pregnancy test at baseline or participants with active project of pregnancy during the study~* Participants with legal incapacity or limited legal capacity~* Participants have participated in any other investigational study within 8 weeks before the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- D-aspartate + IFN beta-1a + Methylprednisolone (Type: EXPERIMENTAL): Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
- Placebo + IFN beta-1a + Methylprednisolone (Type: PLACEBO_COMPARATOR): Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.

Based on this trial design, predict the completion outcome and termination type (if applicable).